TScan Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.89; its P/E ratio is -3.77; TScan Therapeutics is scheduled to report earnings on May 7, 2024, and the estimated EPS forecast is $-0.26. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 7.21M	$ 3.89M	$ 3.15M	$ 6.80M	$ 3.10M
Gross Profit	$ 7.21M	$ 3.89M	$ 3.15M	$ 6.80M	$ 3.10M
EBIT	$ -18.76M	$ -22.02M	$ -23.08M	$ -22.74M	$ -18.65M
EBITDA	$ -17.48M	-	-	$ -21.24M	$ -23.75M
Net Income Common Stockholders	$ -19.61M	$ -23.00M	$ -24.05M	$ -22.56M	$ -18.72M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 192.04M	$ 215.42M	$ 208.84M	$ 95.61M	$ 120.03M
Total Assets	$ 272.15M	$ 291.38M	$ 316.92M	$ 173.58M	$ 199.09M
Total Debt	$ 92.43M	$ 86.98M	$ 87.74M	$ 85.31M	$ 85.98M
Net Debt	$ -99.61M	$ -128.44M	$ -121.10M	$ -10.30M	$ -34.04M
Total Liabilities	$ 121.28M	$ 122.42M	$ 126.32M	$ 95.56M	$ 99.66M
Stockholders Equity	$ 150.87M	$ 168.96M	$ 190.61M	$ 78.02M	$ 99.43M
Cash Flow	-
Free Cash Flow	$ -24.23M	-	-	$ -24.43M	$ -17.39M
Operating Cash Flow	$ -23.77M	$ 8.02M	-	$ -23.59M	$ -16.01M
Investing Cash Flow	$ 1.91M	$ -61.41M	-	$ -838.00K	$ -1.38M
Financing Cash Flow	$ 19.00K	$ -252.00K	-	-	$ 108.00K

Currency in USD

TScan Therapeutics Earnings and Revenue History

Income Statement >

TScan Therapeutics Debt to Assets

Balance Sheet >

TScan Therapeutics Cash Flow

Cash Flow >

TScan Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing